Category Archives: HIV care & treatment

Covered California staff recommends capping specialty prescription drug costs

post_coveredca

Project Inform applauds the recent recommendation by Covered California staff to cap specialty prescription drug costs at $250 per drug per month for 2016 Covered California Silver, Gold and Platinum level plans. The recommendation will be made Thursday, May 21 at the Covered California Board meeting….Read More

VIDEO: How San Francisco plans to ‘get to zero’ new infections of HIV

post_G20

Project Inform is on the steering committee for this effort to bring new HIV infections to zero, along with zero deaths and zero stigma. Watch this PBS video for more information.

CROI2015: New “Kick and Kill” HIV cure drug (TLR7 agonist) from Gilead shows promise

post_croi2015

A new type of drug, called a toll-like receptor 7 (TLR7) agonist, was able to activate HIV-infected CD4 cells from HIV-positive donors on antiretroviral therapy (ART), leading to the release and replication of virus, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic…Read More

CROI2015: Financial incentives don’t increase case linkage or viral suppression

post_croi2015

A large study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle found that offering gift cards to people to reward them for getting into HIV care after testing positive or for getting their viral loads suppressed doesn’t work better than the…Read More

CROI2015: The risk for transmission persists through the first six months of HIV treatment

post_croi2015

At the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, an analysis from the Partners PrEP Study revealed that the risk for HIV transmission within the first six months of starting HIV treatment is still possible before full suppression is attained. Although HIV levels…Read More

CROI2015: Using raltegravir or protease inhibitors influences about equal levels of fat gains

post_croi2015

At the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, the ACTG 5260s study showed increases in body fat after starting a regimen with either raltegravir, boosted darunavir (Prezista) or boosted atazanavir (Reyataz) — with no differences seen between those regimens. Earlier study has…Read More

CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat

post_croi2015

At the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results were presented from a phase 2a study of the new maturation inhibitor, BMS-955176. This “second-generation” drug inhibits HIV in the last steps of its life cycle by preventing it from becoming fully mature…Read More